Project Grant HT94252410331
Award Date 9/30/24
Completion Date 9/29/28
Dollars Obligated $933K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98195, USA
Similar Awards
- This Project Grant award for $699,750 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) to the University of Washington aims to support the discovery and characterization of tissue-specific regulatory mutations that predispose to ovarian cancer. The award will fund research activities over a 3-year period from April 2024 to March 2027. As a leading research university, the University of Washington has extensive experience managing federal grants and...
- The University of Washington received a $622,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research on the fibrolamellar carcinoma tumor microenvironment using human tumor slice cultures. The award has a performance period from July 1, 2024 to June 30, 2026. Through this funding, the University of Washington will investigate innovative approaches to improve understanding of the fibrolamellar carcinoma tumor...
- The Department of Defense's Defense Health Agency awarded a $1,127,375 Project Grant to The Washington University Office of Sponsored Research Services Division under the Military Medical Research and Development program (CFDA 12.420). The grant, which runs from Sep 30, 2023 to Sep 29, 2027, will fund research on "REPLICATION DRIVEN VULNERABILITIES IN CYCLIN E OVEREXPRESSING OVARIAN CANCERS". As a prominent research institution with expertise in biomedical sciences, The Washington...
- The University of Washington received a $617,221 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant funds research to advance the efficacy, longevity, and safety of gene editing therapies for Duchenne muscular dystrophy (DMD). The 2-year grant period runs from August 15, 2023 to August 14, 2025. As a leading research institution, the University of Washington has previously received federal funding to support a...
- The Defense Health Agency awarded a $1,555,000 project grant to the University of Wisconsin System for the "Population Modeling to Optimize Equitable Ovarian Cancer Outcomes" research program under the Military Medical Research and Development (CFDA 12.420) federal grant program. The project, running from April 2025 to April 2029, will focus on advanced biomedical research to transform healthcare for military service members, veterans, and the public by developing novel diagnostic...
- This federal Project Grant award of $459,747.00, awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research at the University of Wisconsin-Madison to define the effect of copy number amplification on the regulation of oncogenes in high-grade serous ovarian carcinoma. The research will examine the contributions of superenhancers at the 8q22 region, with the goal of advancing scientific understanding and potential treatment...
- This Project Grant award of $1,412,000 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports a biorepository and community development project to characterize aggressive urothelial cancer variants. The University of Washington, as the prime awardee, will conduct this research over a period of approximately 4 years, from September 2024 through August 2028. The project aims to expand understanding of aggressive forms of urothelial (bladder)...
- The Defense Health Agency (DHA) awarded the University of Washington a $543,285 Project Grant under the Military Medical Research and Development program (CFDA 12.420) on August 1, 2025, with a completion date of July 31, 2028. This award supports research focused on transforming rhabdomyosarcoma treatment through the development and evaluation of new FDA-approved combination therapies. The project will be conducted at the University of Washington's Seattle, Washington location under the...
- The federal Project Grant award titled "LEVERAGING THE OVARIAN TUMOR MICROENVIRONMENT FOR EARLY DETECTION STRATEGIES" was provided by the Defense Health Agency, which administers the Military Medical Research and Development program (CFDA 12.420). The $466,500 award to The Washington University, a private research institution in University City, Missouri, will support advanced biomedical research to develop innovative diagnostic tools and therapeutic interventions for critical health...
- The U.S. Defense Health Agency awarded a $1,965,204 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to the University of Washington to support the early-stage development of an anti-inflammatory melanocortin fusion protein for tactical combat casualty care. The award period runs from August 1, 2024 to July 31, 2027. This research aims to investigate new therapeutic approaches for improving health outcomes for military service members. As a prominent...